会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • Compound
    • 复合
    • US20100056524A1
    • 2010-03-04
    • US12384477
    • 2009-04-02
    • Edward Giles MciverJustin Stephen BryansEla SmiljanicStephen John LewisJoanne HoughThomas Drake
    • Edward Giles MciverJustin Stephen BryansEla SmiljanicStephen John LewisJoanne HoughThomas Drake
    • A61K31/5377C07D239/02C07D403/12C07D413/12A61K31/505A61K31/506
    • C07D239/48C07D401/12C07D403/12C07D407/12C07D407/14C07D409/12C07D409/14C07D413/12C07D471/04
    • A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein: R1 is C3-8-cycloalkyl; X is O, NR7 or C3-6-heterocycloalkyl; R2 is aryl, heteroaryl, fused or unfused aryl-C3-6-heterocycloalkyl or fused or unfused heteroaryl-C3-6-heterocycloalkyl, each of which is optionally substituted by one or more substitutents selected from aryl, heteroaryl, C1-6-alkyl, C3-7-cycloalkyl and a group A, wherein said C1-6-alkyl group is optionally substituted by one or more substituents selected from aryl, heteroaryl, R10 and a group A, said heteroaryl group is optionally substituted by one or more R10 groups; and wherein said C3-6-heterocycloalkyl group optionally contains one or more groups selected from oxygen, sulfur, nitrogen and CO; R3 is C1-6-alkyl optionally substituted by one or more substituents selected from aryl, heteroaryl, —NR4R5, —OR6, —NR7(CO)R6, —NR7(CO)NR4R5, —NR7SO2R6, —NR7COOR7, —CONR4R5, C3-6-heterocycloalkyl and wherein R4-7 and A are as defined in the claims.Further aspects relate to the use of said compounds in the treatment of various therapeutic disorders, and more particularly as inhibitors of one or more kinases.
    • 本发明的第一方面涉及式(I)化合物或其药学上可接受的盐或酯,其中:R 1为C 3-8 - 环烷基; X是O,NR 7或C 3-6 - 杂环烷基; R 2是芳基,杂芳基,稠合或未稠合的芳基-C 3-6 - 杂环烷基或稠合或未稠合的杂芳基-C 3-6 - 杂环烷基,其各自任选被一个或多个选自芳基,杂芳基,C 1-6 - 烷基 C 3-7 - 环烷基和基团A,其中所述C 1-6 - 烷基任选被一个或多个选自芳基,杂芳基,R 10和A基团的取代基取代,所述杂芳基任选地被一个或多个R 10 团体 并且其中所述C 3-6杂环烷基任选地含有一个或多个选自氧,硫,氮和CO的基团; R 3是任选被一个或多个选自芳基,杂芳基,-NR 4 R 5,-OR 6,-NR 7(CO)R 6,-NR 7(CO)NR 4 R 5,-NR 7 SO 2 R 6,-NR 7 COOR 7,-CONR 4 R 5,C 3 -6-杂环烷基,其中R 4-7和A如权利要求中所定义。 其它方面涉及所述化合物在治疗各种治疗性疾病中的用途,更具体地涉及一种或多种激酶的抑制剂。